Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Items 401–500 of 657
Adetuyi, B. O., & Vega, L. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_239 · Cited by 9
Harnessing cells to improve transport of nanomedicines
Bezze, A., Mattioda, C., Ciardelli, G., & Mattu, C. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114446 · Cited by 3
Liu, T., Pi, H., Chen, B., & Zhang, X. (2024) · 化学学报 · doi:10.6023/a24060181 · Cited by 3
L-Threonine-Derived Biodegradable Polyurethane Nanoparticles for Sustained Carboplatin Release
Oh, S., Park, S., Seo, H. I., & Chung, I. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010028 · Cited by 3
Application of Nanotechnology in Cancer Therapy: Potential and Limitations
Mondal, S., Basu, D., Maiti, B., Ghosh, O., & Ghosh, S. (2024) · Journal of Current Oncological Trends · doi:10.4103/jcot.jcot_17_24 · Cited by 3
Wärnberg, F., Axelsson, O., Curiac, D., Hargreaves, P., Karakatsanis, A., Lekmeechai, S., & Hansen, M. (2025) · Investigative Radiology · doi:10.1097/rli.0000000000001164 · Cited by 3
“23,24 This would need to be strengthened by performing larger, statistically powered clinical studies in the future.”
Zaman, A., & Das, P. K. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500135 · Cited by 3
NALLAMUTHU, M., S., U., & Anandan, R. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i4.54437 · Cited by 4
Nanodrugs against cancer: biological considerations in its redesign
Rios, P. A. F. D. L., Pimentel, R. G. C., & Martín‐Martínez, E. S. (2022) · International Journal of Polymeric Materials · doi:10.1080/00914037.2022.2097680 · Cited by 4
Lotfallah, A. H., Andreu, J. J., Hathout, R. M., Kassem, D. H., Ibrahim, S. S., Altava, B., García‐Verdugo, E., & Luis, S. V. (2022) · Materials Today Chemistry · doi:10.1016/j.mtchem.2022.101266 · Cited by 3
Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines
Nguyen, P.-V., Allard-Vannier, É., Aubrey, N., Labrugère, C., Chourpa, I., Sobilo, J., Pape, A. L., & Hervé-Aubert, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122679 · Cited by 3
“On the other hand, theranostic tools can help track the in vivo journey of therapeutic agents as regards their pharmacokinetics/biodistribution and monitor treatment efficacy by delivering magnetic contrast/fluorescent/radioactive agents [2,3].”
BackgroundLigand free FeSn 2 alloy nanoparticles for safe T 2 -weighted MR imaging of in vivo lung tumors
Thangudu, S., Lin, W., Lee, C., Liao, M.-C., Yu, C., Wang, Y., & Su, C. (2023) · Biomaterials Science · doi:10.1039/d2bm01517j · Cited by 4
Lerchbammer-Kreith, Y., Hejl, M., Sommerfeld, N. S., Weng-Jiang, X., Odunze, U., Mellor, R. D., Workman, D. G., Jakupec, M. A., Schätzlein, A. G., Uchegbu, I. F., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16071027 · Cited by 3
“Thereby, the penetration and accumulation in tumour tissue by molecules in the nanometre range is facilitated [17,18].”
BackgroundJin, K., Zhang, H., Yang, Y., & Gao, Y. (2023) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2263133 · Cited by 3
Current Trends and Future Directions in Nanomedicine: A Review
Kothawade, S. N., Pande, V. V., Bole, S. S., Patil, P. B., Wagh, V. S., Sumbe, R. B., Suyrawanshi, J. S., & Autade, K. A. (2023) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/8gxfwd0svq · Cited by 3
Lin, M.-Y., Wang, C.-Y., Chan, Y., Su, S., Chiang, H. K., Yang, M., & Lee, Y. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0310 · Cited by 3
“The pDots are also nanoparticles that can be taken up by tumors via the enhanced permeability and retention (EPR) effects (Subhan et al., 2021).”
Charge balanced aggregation: A universal approach to aqueous organic nanocrystals
Zhao, W., Li, Q., He, P. L., Li, C., Aryal, M., Fabiilli, M. L., & Xiao, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.017 · Cited by 6
Nano-engineered monoclonal antibodies expanding the newer avenues for cancer targeting
Janakiraman, K., Jayaraj, G., Sethuraman, V., & Krishnaswami, V. (2024) · Macromolecular Research · doi:10.1007/s13233-024-00322-1 · Cited by 3
“…when spreading within tumors due to aberrant tumor blood vessels and elevated interstitial pressure, unlike their propagation in healthy tissues [21]. mAbs consist of two identical light chains and two identical heavy chains that join together to form an antibody, usually linked by a disulfide…”
Rejeeth, C., Almeer, R., Sharma, A., Mesfer, M. K. A., & Danish, M. (2024) · BioNanoScience · doi:10.1007/s12668-024-01643-2 · Cited by 4
“Nanoparticles smaller than 400 nm have been shown to be able to pass through the ERP effect [40], where vascular endothe-lia congregate at tumor locations.”
Sidek, N. A. M., Norpi, A. S. M., Mohamed, M., Ramli, M. Z., Nordin, A. H., Shaharulnizim, N., Mohamad, M. A., Hambali, K. A., Razik, M. A., Ismail, N., et al. (2025) · Annals of Animal Science · doi:10.2478/aoas-2024-0106 · Cited by 4
Bellaye, P., Dias, A. M. M., Vrigneaud, J., Bouchard, A., Moreau, M., Petitot, C., Bernhard, C., Claron, M., Froidurot, L., Morgand, V., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39543 · Cited by 2
AbouAitah, K., Bu, Y., Sharma, M., & Kim, B. S. (2025) · FlatChem · doi:10.1016/j.flatc.2025.100824 · Cited by 2
Molecular Design of Dual Redox-Active Phospholipid Polymers with a Potent Anticancer Activity
Ogawa, Y., Kaneko, M., & Itô, A. (2025) · ACS Applied Polymer Materials · doi:10.1021/acsapm.5c00350 · Cited by 2
Improved apoptosis and mitochondrial dysfunction: the potential of carmofur-platinum nanoparticles
Erdemir, G., Özerkan, D., Kariper, İ. A., Sert, E., Korkut, I. N., & Kalındemirtaş, F. D. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adcbfa · Cited by 2
“The range between 10 and 100 nm range is often considered ideal because nanoparticles are small enough to pass through the leaky vasculature of tumors, but large enough to avoid rapid renal clearance [44].”
Liu, K., Zuo, R., Yu, Y., Chen, X., Wang, T., Xie, L., Sun, H., Niu, M., & Wang, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00527 · Cited by 2
Macro-, micro- and nanoscale drug delivery systems in oncotherapy: current clinical status
Tărăbuță, P. A. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214365 · Cited by 2
Oliveira, F., Pereira, J., Neca, C., Mansor, M. H., Gao, Z., Muthana, M., & Duarte, A. R. C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107517 · Cited by 2
Vasumathi, R., Shetty, M. P., Suvalakshmi, S., Shenoy, R. P., Mutalik, S., & Bharati, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00598 · Cited by 2
Afanasyeva, K. A., Буданова, У. А., Sebyakin, Y. L., Gileva, A. M., Drozdova, M. G., & Арнольдовна, М. Е. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025603660 · Cited by 2
Luke, S., Mohan, S., Prakash, D., Sabir, D. K., Perumal, P., Alomary, M. N., Siva, D., Deenadayalan, V. K., Bhatt, P., & Jacob, J. A. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.116076 · Cited by 2
Nanotherapeutics for Colorectal Cancers Using Nanobiomaterials
Jalise, S. Z., Kheirkhah, A. H., Poondla, N., Sardarabadi, H., & Sheykhhasan, M. (2026) · Nanotechnology in the life sciences · doi:10.1007/978-3-032-08576-4_1 · Cited by 2
ALTAF, S., 1, Q. F., 2, B., RAMZAN, A., 3, M. S., Rani, B., & TABASSUM, R. (2025) · Agrobiological Records · doi:10.47278/journal.abr/2025.049 · Cited by 4
Usmani, Z., Usmani, Z., Ahmad, A., Jahan, S., Akhtar, M., Aqil, M., & Mujeeb, M. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202502609 · Cited by 2
“Such characteristics under-pin the EPR effect, allowing NPs to accumulate within tumor tissue more effectively [ 122, 123 ].”
Advances in Hybrid Nanoparticle Synthesis Through Microfluidics for In-chip Biomedical Studies
Park, J. H., Kong, C., Park, B., Ahn, J., Gupta, V. K., Makvandi, P., Huh, Y. S., & Jang, S. (2026) · BioChip Journal · doi:10.1007/s13206-026-00259-w · Cited by 2
Azizah, J. S., Ngabdi, C. K., Fatiha, R. A., To, S. W., Malek, N. A. N. N., Riawan, W., Holipah, H., Sulistomo, H. W., Lestari, B., & Permatasari, H. K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153407 · Cited by 3
Elgendy, H. A., Elakkad, Y. E., Makky, A. M. A., Khalifa, A. K., & Younes, N. F. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108168 · Cited by 3
Nsairat, H., Azzam, H., Alsanabrah, A., Madi, R., Almullah, M., Alshaer, W., & Ibrahim, A. A. (2026) · South African Journal of Botany · doi:10.1016/j.sajb.2026.04.004 · Cited by 2
Nanoparticles and Nanomaterials for Targeted Drug Delivery: An Updated Review
Aihiokhai, M. O., Orogu, J. O., Ali, A. B. M., Akpo, M. O., Imoni, C. A., Oviri, M. O., Asemota, F. O., Ohwofaraye, G., Edo, G. I., Yousif, E., et al. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00589-z · Cited by 4
Biosynthesis of precious metal nanoparticles using green algae extracts for cancer therapy
Alven, S., Mnyamana, S., Gandidzanwa, S., & Tshentu, Z. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.214907 · Cited by 3
Rahaman, Jalouli, M., Harrath, A. H., Choi, J., Choi, M., Kim, H. S., Park, S., Shim, B., Rani, A., & Kim, B. (2026) · Cells · doi:10.3390/cells15100850 · Cited by 2
“The EPR effect allows nanoparticles to accumulate within tumor tissue [45].”
Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma
Bătrîna, O., Negrea-Ghiulai, R., Suciu, L., Racoviceanu, R., Atyim, E., Jorgovan, M., Maksimović, T., Mioc, A., Trandafirescu, C. M., Şoica, C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104423 · Cited by 3
AI Driven Computational Nanomedicine for Personalized Cancer Therapy
Farghama, K., Khan, M. S., Wajid, M., & Shaffique, S. (2026) · BioNanoScience · doi:10.1007/s12668-026-02681-8 · Cited by 2
Liu, X., Wang, Y., Zou, J., Wang, H., Li, X., Huang, Y., Hu, E., Guan, Z., Quan, D., Liu, J., et al. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01802k · Cited by 2
Nanoparticle Targeting Strategies In Cancer Therapy
Balyapan, H., & Ak, G. (2023) · Recent advances in biotechnology · doi:10.2174/9789815179422123080010 · Cited by 2
Nanotechnology-based Approaches for Breast Cancer
Prabha, S., Panda, P. K., Singh, S., & Ahmed, B. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947282469240212075845 · Cited by 2
Liu, Y., Su, M., Wang, Y., Du, Y., Wang, Y., & Hu, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27408 · Cited by 2
“How to enhance permeability and improve retention of nanomaterials in tumors after systemic administration remains a difficult hot topic [10].”
BackgroundDesign of SAHA-Loaded PLGA Nanoparticles Aimed for Use in Breast Cancer Combination Therapy
Gulyaev, I. A., Sokol, M. B., Klimenko, M. A., Mollaeva, M. R., Yabbarov, N. G., Chirkina, M., & Nikolskaya, E. D. (2023) · Physics of Atomic Nuclei · doi:10.1134/s1063778823110170 · Cited by 2
Tumor Microenvironment-Responsive Nanoplatforms for Triggering Drug Delivery
Melia, F., Udomjarumanee, P., Rogoyski, R., & Pranjol, M. Z. I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_412-1 · Cited by 2
Personalized Nanoparticles for Cancer Therapy
Sahoo, S., Mohapatra, P., & Sahoo, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-3545-7_7 · Cited by 3
Nanoparticles: A Treatment Modality for Lung Cancer
Abdullah, S., Goher, F., & Awan, A. N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_306 · Cited by 2
Advancements in nanomedicine: Targeted drug delivery systems for cancer treatment
Alajmi, A., Otaibi, S. G. A., Alzubidi, A. H. A., Alanazi, A. A. A., Almorshed, A. S. A., & Alrbian, A. A. M. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7ns1.15291 · Cited by 2
Martin-Aubert, S., Avrillon, K., Tournier, N., Bordat, A., Tran, V. L., Ibrahim, N., Kereselidze, D., Jégo, B., Potiron, L., Tsapis, N., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.050 · Cited by 2
Fahmy, A. M. (2025) · Premier journal of science. · doi:10.70389/pjs.100052 · Cited by 2
Živković, M. P., Andric, F., Svicevic, M. R., Krstic, D. Z., Krstić, L., Pirkovic, B., Miladinović, T. B., & Aichouche, M. E. A. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108838 · Cited by 2
Udaipuria, N., & Bhattacharya, S. (2025) · International Journal of Polymeric Materials · doi:10.1080/00914037.2025.2558674 · Cited by 2
The role of nanotechnology: Organic nanomaterials and the mechanism of cancer phototheranostics
Bukhari, S. Z., Iftikhar, M., Ihsan, A., & Younis, M. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95758-8.00008-3 · Cited by 3
Kırmızıtaş, F. C., Demirbilek, M., & Laçin, N. T. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4875267 · Cited by 2
NANOCÁPSULAS DE NÚCLEO LIPÍDICO: PREPARAÇÃO, CARACTERIZAÇÃO E APLICAÇÕES BIOLÓGICAS
Dallemole, D. R., Ciocheta, T. M., Frank, L. A., Alves, A. D. C. S., Pacheco, B. Z., Guterres, S. S., Paese, K., & Pohlmann, A. R. (2023) · Química Nova · doi:10.21577/0100-4042.20230077 · Cited by 1
Moulahoum, H., Ghorbanizamani, F., Tok, K., & Zihnioğlu, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19012-4.00019-9 · Cited by 4
Nanoparticulate Herbal Formulation for the Management of Fungal Infection
Gupta, B., Malviya, R., Sundram, S., & Singh, B. (2024) · Nanoscience & Nanotechnology-Asia · doi:10.2174/0122106812329611240913161126 · Cited by 1
Nanotechnology based approaches for leukemia therapy
(2024) · Biomedical Letters · doi:10.47262/bl/10.2.20241021 · Cited by 1
Advanced materials for cancer treatment and beyond
Zhang, L., Wang, Y., Li, Y., Chen, Z., & Hu, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1557155 · Cited by 1
Unraveling the Role of Tumor-infiltrating Immune Cells in Modulating Cancer Drug Resistance
Mehrabadi, S. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206365310250310081445 · Cited by 2
Bioorthogonal catalytic microvesicle-mediated prodrug activation against liver cancer
Wan, X., Liu, X., Wu, P., Li, Y., Shi, Y., Nie, Y., Zhang, K., Jin, Z., Song, R., Zhang, Z., et al. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103774 · Cited by 1
Functional quantum dots in drug delivery
Arora, K., Sherilraj, P. M., & Mudavath, S. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24064-5.00012-3 · Cited by 1
Banerjee, A., & Arora, D. (2025) · Wiley eBooks · doi:10.1002/9781394313785.ch4 · Cited by 1
Bellat, V., Glaser, A. K., Gong, H., Gill, A., Lee, Y. J., Cifani, P., Stokol, T., Vahdat, L. T., & Law, B. (2025) · ACS Nano · doi:10.1021/acsnano.5c02176 · Cited by 1
Tatar, C., & Erdemir, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107499 · Cited by 1
A Comprehensive Review on the Potential of Charged Dendrimers in Pharmaceutical Development
Karati, D., Mukherjee, S., Prajapati, B. G., Basu, B., & Das, B. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00492-z · Cited by 3
Wang, Y., Wu, P., Zhang, Y., Lou, S., Zhang, H., Ge, K., Zhou, L., Liu, W., Yang, L., & Shen, R. (2025) · Talanta · doi:10.1016/j.talanta.2025.129211 · Cited by 1
Mytych, W., Bartusik‐Aebisher, D., Aebisher, D., & Henrykowska, G. A. (2025) · Molecules · doi:10.3390/molecules30244773 · Cited by 1
“In highly proliferating cells, a positive correlation between division rate and CME activity is observed, while long-term retention depends mainly on EPR rather than proliferation [36,37].”
Irfan, M., Sagheer, H., & Elahi, M. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00529-3 · Cited by 1
Surface Engineering of Carbon Nano-Onions for Folic Acid-Mediated Targeted Chemotherapeutic Delivery
Bartkowski, M., Zhou, Y., Penna, I., Russo, D., Mohan, H., Serodre, T., Anglaret, É., Bandiera, T., & Giordani, S. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c05169 · Cited by 1
Efficient non-viral siRNA carriers for triple-negative breast cancer: advances in 2020 − 2025
Liu, W., Wang, Y., & Zhao, X. (2026) · Materials & Design · doi:10.1016/j.matdes.2026.115506 · Cited by 1
First Report of Histotripsy-Induced Survival Benefit in Murine Glioblastomas
Duclos, S. E., Kaovasia, T. P., Fox, A., Cornett, A. M., Pandey, A. S., & Xu, Z. (2026) · Cancers · doi:10.3390/cancers18040622 · Cited by 1
“The 10 PPL protocol was used for larger tumors to account for increased mechanical heterogeneity, including necrotic cores, stiffer peripheral regions, and increased tumor cell density and interstitial fluid pressure [23,24].”
Engineered Nano Polymer-Based Hydrogel
Sharma, A., Dheer, D., & Puri, V. (2026) · Engineering materials · doi:10.1007/978-981-95-3581-1_5 · Cited by 1
Innovative Nanocarrier Strategies for Enhanced Docetaxel Delivery in Cancer Therapy
Kolhe, O., & Ratnaparkhi, M. P. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i3.7601 · Cited by 1
Moon, D., Kim, D., Balwe, S. G., & Song, J. M. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04354-w · Cited by 2
Zhao, X., Zhang, H., Ma, D., Ma, J., Wang, W., Li, X., Fan, H., Wang, C., Zhang, J., Shao, P., et al. (2026) · Biomedical Materials · doi:10.1088/1748-605x/ae59db · Cited by 1
“Despite these advantages, most polysaccharide-based systems depend on passive accumulation, which limits targeting precision and therapeutic efficacy [18].”
Ahalwat, S., Yadav, S., Chauhan, M., Rawat, A., & Dahiya, R. (2026) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2026.101645 · Cited by 3
Chang, Y.-C., Huang, W.-L., Su, W., Leung, E. Y., Cheng, F., & Cheung, C. H. A. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s588571 · Cited by 1
“79,80 Therefore, while our PL-MNP size (~390 nm) is compatible with reported effective nanoparticle sizes in some models, the extent to which EPR contributes to tumor accumulation in human cancers remains uncertain and will require validation in more clinically relevant models and imaging…”
Ferdushi, R., Park, S., & Key, J. (2026) · Carbohydrate Research · doi:10.1016/j.carres.2026.109944 · Cited by 2
Bakir, M. A., Alkhatib, A. R., Mustafa, A. R., Raddaoui, M., Al-Kattan, W., & Mohammad, K. S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050571 · Cited by 2
Recent advances in health hazard and risk assessment nanoparticles
Basudan, N. S. (2026) · Main Group Chemistry · doi:10.1177/10241221261434630 · Cited by 1
Advancing the Therapeutic Potential of Swertia Species Through Nanoformulation Strategies
Yadav, A., Sharma, C., & Priyadarshini, E. (2026) · International Journal of Nanoscience · doi:10.1142/s0219581x26300051 · Cited by 1
Nanocomposite based on silk fibroin and alginate for tumor-targeted gene delivery
Cao, W., Wang, H., Zhang, J., Xie, S., Zhang, J., & Meng, X. (2026) · Industrial Crops and Products · doi:10.1016/j.indcrop.2026.123083 · Cited by 1
Nanotechnology-enabled drug delivery of chalcones: Advances, challenges, and future perspectives
Al-Samydai, A. M., Al-Sahlawi, F., Ahmed, R. M., Al-Sammarraie, T. R., Agha, A. S. A. A., Al-Tamimi, O. H., Jayant, G., Akeel, H., & Carradori, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43812-7.00002-2 · Cited by 1
Dima, C. V., Assadpour, E., Nechifor, A., & Jafari, S. M. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115825 · Cited by 1
El‐Mallul, A., Kowalska, M. K., Sawicka, K., Orłowska, S. M., Bednarczyk, Ł., & Radziszewska, Ł. (2026) · Applied Sciences · doi:10.3390/app16115416 · Cited by 1
Rare earth nanoparticles: Illuminating the future of precision photodynamic therapy in oncology
(254423), H. W., Li, Z., Liao, J., Nie, Q., Lin, Q., Qi, T., & Luo, X. (2026) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2026.113496 · Cited by 1
Velmurugan, R., Helinto, J. S., Subhashri, S., & Ravikumar, L. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100551 · Cited by 1
Gunbay, S., Özbek, S. S., Çakırlı, E., Sala, O. B., & Demirbolat, G. M. (2026) · Discover Nano · doi:10.1186/s11671-026-04750-z · Cited by 1
“This size range supports passive tumor targeting because the enhanced permeation and retention effect markedly facilitates small particle penetration into the tumor microenvironment [18].”
Li, X., Lv, W., Huang, C., Dou, W., Qian, J., Chen, Z., & Liu, H. (2026) · European journal of medical research · doi:10.1186/s40001-026-04822-x · Cited by 1
Kah, G., & Abrahamse, H. (2026) · RSC Advances · doi:10.1039/d6ra03514k · Cited by 1
Jaroniek, P., Brzeziński, M., Świniarska, Z., Chmiela, M., & Gonciarz, W. (2026) · Molecules · doi:10.3390/molecules31142520 · Cited by 1
Abramova, A. A., Rogachev, V. V., Baimler, I. V., Gudkov, S. V., & Varlamova, E. G. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05288-y · Cited by 1
Decoding the uptake pathway of nanoparticles in tumor cells: mechanisms, developments and challenges
Chen, Z., Zhou, L., Li, S., & Zhang, X. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.104054 · Cited by 1
Protein and Peptide-Based Therapeutics for Cancer Imaging
Aluri, S. R. (2022) · Springer eBooks · doi:10.1007/978-3-031-09636-5_16 · Cited by 2
Nanomedicine and nanocarriers for cancer treatment
Natarajan, A., & Kirubavathy, S. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00001-8 · Cited by 2
Drug Delivery Systems for Natural Medicines in Cancer Therapy
Hashim, P. K., Naseef, P. P., Cheruthu, N. M., & Kuruniyan, M. S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266315985240710063754 · Cited by 1
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.